Ranibizumab for Neovascularization in Sickle Cell Retinopathy

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Kresge Eye Institute
Study ID
NCT00618644
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab — DRUG
    Ranibizumab 0.5 mg intravitreal injection

Study Details

The purpose of this study is to determine the ocular and non-ocular safety of a single dose of ranibizumab in treating neovascularization secondary to sickle cell retinopathy.

Key Dates

First listed
Feb 20, 2008
Start date
Jan 31, 2010
Status verified
Sep 2012
Primary completion
Jun 30, 2011
Completion
Jun 30, 2011

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Ranibizumab injection

Primary Outcome Measure

Ocular safety of a single dose of ranibizumab [ Time Frame: Three months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Kresge Eye InstituteDetroitMichigan48201-

Find similar trials in Detroit, MI

By condition
Sickle cell disease
By research site
Kresge Eye Institute· Detroit, MI

Related Studies